These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 37751205

  • 1. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.
    Ko HY, Bea S, Jeong HE, Park S, Cho YM, Kong SH, Shin JY.
    JAMA Netw Open; 2023 Sep 05; 6(9):e2335797. PubMed ID: 37751205
    [Abstract] [Full Text] [Related]

  • 2. Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.
    Richardson TL, Halvorson AE, Hackstadt AJ, Hung AM, Greevy R, Grijalva CG, Elasy TA, Roumie CL.
    Ann Intern Med; 2023 Jun 05; 176(6):751-760. PubMed ID: 37155984
    [Abstract] [Full Text] [Related]

  • 3. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC, Lip GYH.
    Cardiovasc Diabetol; 2022 Jun 28; 21(1):118. PubMed ID: 35765074
    [Abstract] [Full Text] [Related]

  • 4. Second-Line Pharmaceutical Treatments for Patients with Type 2 Diabetes.
    Vashisht R, Patel A, Dahm L, Han C, Medders KE, Mowers R, Byington CL, Koliwad SK, Butte AJ.
    JAMA Netw Open; 2023 Oct 02; 6(10):e2336613. PubMed ID: 37782497
    [Abstract] [Full Text] [Related]

  • 5. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, Sing CW, Cheung CL.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2251177. PubMed ID: 36648944
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B, Hwang YJ, Selvin E, Jameson BC, Chang AR, Grams ME, Shin JI.
    J Gen Intern Med; 2023 Jan 03; 38(1):107-114. PubMed ID: 35831767
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
    Jeong HE, Park S, Noh Y, Bea S, Filion KB, Yu OHY, Jang SH, Cho YM, Yon DK, Shin JY.
    BMC Med; 2023 Feb 10; 21(1):47. PubMed ID: 36765407
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.
    Ha KH, Kim DJ, Choi YJ.
    J Diabetes Investig; 2022 Jun 10; 13(6):986-996. PubMed ID: 35132815
    [Abstract] [Full Text] [Related]

  • 14. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY, Yang CT, Kuo S, Wu CH, Lin WH, Ou HT.
    JAMA Netw Open; 2022 Dec 01; 5(12):e2246928. PubMed ID: 36520437
    [Abstract] [Full Text] [Related]

  • 15. Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong.
    Lui DTW, Wu T, Tang EHM, Au ICH, Lee CH, Woo YC, Tan KCB, Wong CKH.
    Diabetes Res Clin Pract; 2023 Mar 01; 197():110576. PubMed ID: 36780955
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, Zhang Q, Chang C, Liu T, Tse G, Jing F, Cheung BMY.
    Rheumatology (Oxford); 2023 Apr 03; 62(4):1501-1510. PubMed ID: 36066415
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: A propensity score-matched cohort study.
    Adimadhyam S, Lee TA, Calip GS, Smith Marsh DE, Layden BT, Schumock GT.
    Pharmacoepidemiol Drug Saf; 2019 Dec 03; 28(12):1629-1639. PubMed ID: 31646732
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.